OBJECTIVES: To compare treatment outcomes by starting CD4 cell counts using data from the Comprehensive International Program of Research on AIDS-South Africa trial. DESIGN: An observational cohort study. METHODS:Patients presenting to primary care clinics with CD4 cell counts below 350 cells/microl were randomized to either doctor or nurse-managed HIV care and followed for at least 2 years after antiretroviral therapy (ART) initiation. Clinical and laboratory outcomes were compared by baseline CD4 cell counts. RESULTS:Eight hundred and twelve patients were followed for a median of 27.5 months and 36% initiated ART with a CD4 cell count above 200 cells/microl. Although 10% of patients failed virologically, the risk was nearly double among those with a CD4 cell count of 200 cells/microl or less vs. above 200 cells/microl (12.2 vs. 6.8%). Twenty-one deaths occurred, with a five-fold increased risk for the low CD4 cell count group (3.7 vs. 0.7%). After adjustment, those with a CD4 cell count of 200 cells/microl had twice the risk of death/virologic failure [hazard ratio 1.9; 95% confidence interval (CI), 1.1-3.3] and twice the risk of incident tuberculosis (hazard ratio 1.90; 95% CI, 0.89-4.04) as those above 200 cells/microl. Those with either a CD4 cell count of 200 cells/microl or less (hazard ratio 2.1; 95% CI, 1.2-3.8) or a WHO IV condition (hazard ratio 2.9; 95% CI, 0.93-8.8) alone had a two-to-three-fold increased risk of death/virologic failure vs. those with neither, but those with both conditions had a four-fold increased risk (hazard ratio 3.9; 95% CI, 1.9-8.1). We observed some decreased loss to follow-up among those initiating ART at less than 200 cells/microl (hazard ratio 0.79; 95% CI, 0.50-1.25). CONCLUSION: Patients initiating ART with higher CD4 cell counts had reduced mortality, tuberculosis and less virologic failure than those initiated at lower CD4 cell counts. Our data support increasing CD4 cell count eligibility criteria for ART initiation.
RCT Entities:
OBJECTIVES: To compare treatment outcomes by starting CD4 cell counts using data from the Comprehensive International Program of Research on AIDS-South Africa trial. DESIGN: An observational cohort study. METHODS:Patients presenting to primary care clinics with CD4 cell counts below 350 cells/microl were randomized to either doctor or nurse-managed HIV care and followed for at least 2 years after antiretroviral therapy (ART) initiation. Clinical and laboratory outcomes were compared by baseline CD4 cell counts. RESULTS: Eight hundred and twelve patients were followed for a median of 27.5 months and 36% initiated ART with a CD4 cell count above 200 cells/microl. Although 10% of patients failed virologically, the risk was nearly double among those with a CD4 cell count of 200 cells/microl or less vs. above 200 cells/microl (12.2 vs. 6.8%). Twenty-one deaths occurred, with a five-fold increased risk for the low CD4 cell count group (3.7 vs. 0.7%). After adjustment, those with a CD4 cell count of 200 cells/microl had twice the risk of death/virologic failure [hazard ratio 1.9; 95% confidence interval (CI), 1.1-3.3] and twice the risk of incident tuberculosis (hazard ratio 1.90; 95% CI, 0.89-4.04) as those above 200 cells/microl. Those with either a CD4 cell count of 200 cells/microl or less (hazard ratio 2.1; 95% CI, 1.2-3.8) or a WHO IV condition (hazard ratio 2.9; 95% CI, 0.93-8.8) alone had a two-to-three-fold increased risk of death/virologic failure vs. those with neither, but those with both conditions had a four-fold increased risk (hazard ratio 3.9; 95% CI, 1.9-8.1). We observed some decreased loss to follow-up among those initiating ART at less than 200 cells/microl (hazard ratio 0.79; 95% CI, 0.50-1.25). CONCLUSION:Patients initiating ART with higher CD4 cell counts had reduced mortality, tuberculosis and less virologic failure than those initiated at lower CD4 cell counts. Our data support increasing CD4 cell count eligibility criteria for ART initiation.
Authors: Stephen R Cole; Rui Li; Kathryn Anastos; Roger Detels; Mary Young; Joan S Chmiel; Alvaro Muñoz Journal: Stat Med Date: 2004-11-15 Impact factor: 2.373
Authors: Rochelle P Walensky; Lindsey L Wolf; Robin Wood; Mariam O Fofana; Kenneth A Freedberg; Neil A Martinson; A David Paltiel; Xavier Anglaret; Milton C Weinstein; Elena Losina Journal: Ann Intern Med Date: 2009-07-20 Impact factor: 25.391
Authors: David Coetzee; Katherine Hildebrand; Andrew Boulle; Gary Maartens; Francoise Louis; Veliswa Labatala; Hermann Reuter; Nonthutuzelo Ntwana; Eric Goemaere Journal: AIDS Date: 2004-04-09 Impact factor: 4.177
Authors: Jonathan E Kaplan; Debra L Hanson; David L Cohn; John Karon; Susan Buskin; Melanie Thompson; Patricia Fleming; Mark S Dworkin Journal: Clin Infect Dis Date: 2003-09-12 Impact factor: 9.079
Authors: Janne Estill; Cindy Aubrière; Matthias Egger; Leigh Johnson; Robin Wood; Daniela Garone; Thomas Gsponer; Gilles Wandeler; Andrew Boulle; Mary-Ann Davies; Timothy B Hallett; Olivia Keiser Journal: AIDS Date: 2012-07-17 Impact factor: 4.177
Authors: Matthew P Fox; Mhairi Maskew; A Patrick MacPhail; Lawrence Long; Alana T Brennan; Daniel Westreich; William B MacLeod; Pappie Majuba; Ian M Sanne Journal: Int J Epidemiol Date: 2012-03-20 Impact factor: 7.196
Authors: Kate Clouse; Audrey Pettifor; Mhairi Maskew; Jean Bassett; Annelies Van Rie; Cynthia Gay; Frieda Behets; Ian Sanne; Matthew P Fox Journal: AIDS Date: 2013-02-20 Impact factor: 4.177
Authors: Abigail M Hatcher; Janet M Turan; Hannah H Leslie; Lucy W Kanya; Zachary Kwena; Malory O Johnson; Starley B Shade; Elizabeth A Bukusi; Alexandre Doyen; Craig R Cohen Journal: AIDS Behav Date: 2012-07
Authors: Stephen D Lawn; Lucy Campbell; Richard Kaplan; Andrew Boulle; Morna Cornell; Bernhard Kerschberger; Carl Morrow; Francesca Little; Matthias Egger; Robin Wood Journal: J Acquir Immune Defic Syndr Date: 2011-06-01 Impact factor: 3.731
Authors: Jennifer L Glick; Rienna G Russo; Aimee Kao-Hsuan Huang; Belinda Jivapong; Vijayasundaram Ramasamy; Lori M Rosman; Danielle L Pelaez; Susan G Sherman Journal: Glob Public Health Date: 2020-12-10